| Declining prevalence of HIV-1 drug resistance in antiretroviral treatment-exposed individuals in Western Europe A De Luca, D Dunn, M Zazzi, R Camacho, C Torti, I Fanti, R Kaiser, ... The Journal of infectious diseases 207 (8), 1216-1220, 2013 | 89 | 2013 |
| Selecting anti-HIV therapies based on a variety of genomic and clinical factors M Rosen-Zvi, A Altmann, M Prosperi, E Aharoni, H Neuvirth, ... Bioinformatics 24 (13), i399-i406, 2008 | 85 | 2008 |
| Comparison of HIV-1 genotypic resistance test interpretation systems in predicting virological outcomes over time D Frentz, CAB Boucher, M Assel, A De Luca, M Fabbiani, F Incardona, ... PloS one 5 (7), e11505, 2010 | 83 | 2010 |
| Comparison of classifier fusion methods for predicting response to anti HIV-1 therapy A Altmann, M Rosen-Zvi, M Prosperi, E Aharoni, H Neuvirth, E Schülter, ... PloS one 3 (10), e3470, 2008 | 73 | 2008 |
| Predicting response to antiretroviral treatment by machine learning: the EuResist project M Zazzi, F Incardona, M Rosen-Zvi, M Prosperi, T Lengauer, A Altmann, ... Intervirology 55 (2), 123-127, 2012 | 69 | 2012 |
| Prediction of response to antiretroviral therapy by human experts and by the EuResist data‐driven expert system (the EVE study) M Zazzi, R Kaiser, A Sönnerborg, D Struck, A Altmann, M Prosperi, ... HIV medicine 12 (4), 211-218, 2011 | 55 | 2011 |
| Detection of drug resistance mutations at low plasma HIV-1 RNA load in a European multicentre cohort study MCF Prosperi, N Mackie, S Di Giambenedetto, M Zazzi, R Camacho, ... Journal of antimicrobial chemotherapy 66 (8), 1886-1896, 2011 | 39 | 2011 |
| Determinants of HIV-1 late presentation in patients followed in Europe MNS Miranda, M Pingarilho, V Pimentel, MRO Martins, AM Vandamme, ... Pathogens 10 (7), 835, 2021 | 27 | 2021 |
| Trends of transmitted and acquired drug resistance in Europe from 1981 to 2019: a comparison between the populations of late presenters and non-late presenters MNS Miranda, M Pingarilho, V Pimentel, MRO Martins, R Kaiser, ... Frontiers in Microbiology 13, 846943, 2022 | 23 | 2022 |
| Advantages of predicted phenotypes and statistical learning models in inferring virological response to antiretroviral therapy from HIV genotype A Altmann, T Sing, H Vermeiren, B Winters, EV Craenenbroeck, ... Antiviral Therapy 14 (2), 273-283, 2009 | 19 | 2009 |
| PhyloGeoTool: interactively exploring large phylogenies in an epidemiological context P Libin, E Vanden Eynden, F Incardona, A Nowé, A Bezenchek, ... Bioinformatics 33 (24), 3993-3995, 2017 | 18 | 2017 |
| Stochastic modelling of genotypic drug-resistance for human immunodeficiency virus towards long-term combination therapy optimization MCF Prosperi, R D'Autilia, F Incardona, A De Luca, M Zazzi, G Ulivi Bioinformatics 25 (8), 1040-1047, 2009 | 18 | 2009 |
| Drug resistance testing through remote genotyping and predicted treatment options in human immunodeficiency virus type 1 infected Tanzanian subjects failing first or second … J Svärd, S Mugusi, D Mloka, U Neogi, G Meini, F Mugusi, F Incardona, ... PloS one 12 (6), e0178942, 2017 | 17 | 2017 |
| Evaluation of HIV-1 integrase resistance emergence and evolution in patients treated with integrase inhibitors R Scutari, C Alteri, I Vicenti, D Di Carlo, V Zuccaro, F Incardona, V Borghi, ... Journal of Global Antimicrobial Resistance 20, 163-169, 2020 | 16 | 2020 |
| Supporting Iraqi Kurdistan health authorities in post-conflict recovery: the development of a health monitoring system L Emberti Gialloreti, FB Basa, S Moramarco, AO Salih, HH Alsilefanee, ... Frontiers in public health 8, 7, 2020 | 16 | 2020 |
| Earlier initiation of antiretroviral treatment coincides with an initial control of the HIV-1 sub-subtype F1 outbreak among men-having-sex-with-men in Flanders, Belgium L Vinken, K Fransen, L Cuypers, I Alexiev, C Balotta, L Debaisieux, ... Frontiers in microbiology 10, 613, 2019 | 15 | 2019 |
| Future challenges and recommendations V Jones, F Incardona, C Tristram, S Virtuoso, A Lymberis M-Health: Emerging Mobile Health Systems, 267-270, 2006 | 15 | 2006 |
| Clinical use, efficacy, and durability of maraviroc for antiretroviral therapy in routine care: A European survey A De Luca, P Pezzotti, C Boucher, M Döring, F Incardona, R Kaiser, ... PLoS One 14 (11), e0225381, 2019 | 14 | 2019 |
| Efficacy of etravirine combined with darunavir or other ritonavir‐boosted protease inhibitors in HIV‐1‐infected patients: an observational study using pooled E uropean cohort data J Vingerhoets, V Calvez, P Flandre, AG Marcelin, ... HIV medicine 16 (5), 297-306, 2015 | 14 | 2015 |
| Pre‐existing singleton E138A mutations in the reverse transcriptase gene do not affect the efficacy of first‐line antiretroviral therapy regimens using rilpivirine in human … A Kuznetsova, A Lebedev, K Gromov, E Kazennova, M Zazzi, F Incardona, ... Clinical case reports 10 (2), e05373, 2022 | 12 | 2022 |
